Teva Pharmaceuticals sued Biogen International Gmbh for breach of contract on Friday in New Jersey District Court. The suit, filed by Shook, Hardy & Bacon, brings claims in connection with an agreement for the supply by Biogen and the distribution by Teva of an authorized generic version of Tecfidera, Biogen’s branded treatment for multiple sclerosis. The suit, which is heavily redacted, claims that Biogen improperly terminated the agreement without compensating Teva. Counsel have not yet appeared for Biogen. The case is 2:23-cv-02491, Teva Pharmaceuticals USA, Inc. v. Biogen International Gmbh.

This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]